Known as Covifenz, the vaccine was developed by Medicago, a biotechnology company based in Quebec City that uses a plant host to make virus−like particles which help the body’s immune system make antibodies.
Health Canada's chief medical adviser says variant-specific vaccines can be approved faster than the general ones first issued to combat COVID-19, but one targeting the Omicron strain still likely won't be ready in time to help with the latest wave.
Canadian provinces suspended use of the Oxford-AstraZeneca COVID-19 vaccine in people under age 55 on Monday, March 29, 2021, acting on an advisory committee's concerns about a possible link between the shot and rare blood clots.
Canada's chief medical adviser says her department is constantly receiving and reviewing any data on vaccines and COVID-19 variants and will be ready to quickly authorize needed boosters when they're available.
Essential workers who are more likely to contract and transmit COVID-19 should be prioritized for immunization with the Oxford-AstraZeneca vaccine now that a national panel is not recommending it for seniors, two experts say.